<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01197794</url>
  </required_header>
  <id_info>
    <org_study_id>D9830C00008</org_study_id>
    <secondary_id>2010-020407-73</secondary_id>
    <nct_id>NCT01197794</nct_id>
  </id_info>
  <brief_title>Investigation of Efficacy, Safety and Tolerability of Once and Twice Daily Doses of AZD1981 in Asthmatic Patients</brief_title>
  <acronym>Sweapea</acronym>
  <official_title>A Double-blind, Placebo-controlled, Randomised, Parallel-group, Phase II, Multi-centre Study to Assess the Efficacy, Safety and Tolerability of 4 Twice Daily Doses and 2 Once Daily Doses of AZD1981 Given as Tablets During 12 Weeks in Asthmatic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the efficacy, safety and tolerability of AZD1981 compared to non-active
      compound in asthmatic patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-bronchodilator FEV1 at the Clinic</measure>
    <time_frame>Twelve week treatment period</time_frame>
    <description>Change from baseline: treatment period average minus baseline. Treatment period average defined as the mean of all available data during randomized treatment that occurred on or prior to treatment failure. Treatment failure defined as worsening asthma symptoms resulting in increased dose of inhaled corticosteroid.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morning and Evening PEF</measure>
    <time_frame>Twelve week treatment period</time_frame>
    <description>Change from baseline: treatment period average minus baseline. Treatment period average defined as the mean of all available morning (evening) PEF during randomized treatment that occurred on or prior to treatment failure. Treatment failure defined as worsening asthma symptoms resulting in increased dose of inhaled corticosteroid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control Questionnaire 5-item (ACQ5)</measure>
    <time_frame>Twelve week treatment period</time_frame>
    <description>The ACQ5 consists of 5 questions, each assessed on a scale from 0-6, where 0 represents good asthma control and 6 represents poor asthma control. The overall score is the mean of the responses. The minimal important difference is defined as a change in score of 0.5. Change from baseline: treatment period average minus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Twelve week treatment period</time_frame>
    <description>Number of participants who had at least one adverse event during the randomized treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Severe Asthma Exacerbation</measure>
    <time_frame>Twelve week treatment period</time_frame>
    <description>Severe asthma exacerbation defined as deterioration in asthma leading to either hospitalization/emergency room treatment or oral glucocorticosteroid treatment for at least 3 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Treatment Failure</measure>
    <time_frame>Twelve week treatment period</time_frame>
    <description>Treatment failure is defined as a clinical need for additional inhaled corticosteroid use as judged by the investigator based on evaluations at the clinic.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Well-controlled Asthma (ACQ5&lt;=0.75)</measure>
    <time_frame>Twelve week treatment period</time_frame>
    <description>The ACQ5 consists of 5 questions, each assessed on a scale from 0-6, where 0 represents good asthma control and 6 represents poor asthma control. The overall score is the mean of the responses. Well-controlled asthma is defined as ACQ5&lt;=0.75 at the end of the 12-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Quality of Life Questionnaire (AQLQ(S))</measure>
    <time_frame>Twelve week treatment period</time_frame>
    <description>The AQLQ(S) consists of 32 questions, each assessed on a scale from 1-7, with higher values indicating better health-related quality of life. Overall scores are calculated from the means of the individual scores. The minimal important difference is a change in score of 0.5. Change from baseline: treatment period average minus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Symptom Score</measure>
    <time_frame>Twelve week treatment period</time_frame>
    <description>Asthma symptoms, measured in the morning and evening, based on a scale from 0-3 with higher scores indicating more severe asthma symptoms. Total asthma symptom score (0-6) is calculated by taking the sum of the morning and evening scores. Change from baseline: treatment period average minus baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Reliever Medication Use</measure>
    <time_frame>Twelve week treatment period</time_frame>
    <description>Reliever medication use (number of inhalations), measured in the morning and evening. Total reliever medication use is calculated by taking the sum of the number of daytime and evening inhalations of reliever medication. Change from baseline: treatment period average minus baseline.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">1144</enrollment>
  <condition>Asthma Patients</condition>
  <arm_group>
    <arm_group_label>AZD1981 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 10 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD1981 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD1981 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 100 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD1981 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD1981 80 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 80 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD1981 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD1981 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>AZD1981 twice daily</description>
    <arm_group_label>AZD1981 10 mg</arm_group_label>
    <arm_group_label>AZD1981 40 mg</arm_group_label>
    <arm_group_label>AZD1981 100 mg</arm_group_label>
    <arm_group_label>AZD1981 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1981</intervention_name>
    <description>AZD1981 once daily</description>
    <arm_group_label>AZD1981 80 mg</arm_group_label>
    <arm_group_label>AZD1981 200 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match AZD1981</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women. Women must be surgically sterilized/postmenopausal or use double
             barrier method contraception

          -  6 months history of asthma according to ATS definition

          -  Prescribed daily dose of ICS and LABA for at least 3 months prior to Visit 2

          -  Pre-bronchodilator FEV1 of 40 to 85 % of predicted normal

          -  A total ACQ5 score of 1.5 or more

        Exclusion Criteria:

          -  Respiratory infection significantly affecting the asthma

          -  Any significant disease and disorder that may put the patient at risk or influence
             study results

          -  Any clinically relevant abnormal findings

          -  A smoking history of more than 10 pack years

          -  Intake of oral, rectal or parenteral glucocorticosteroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chris O'Brien, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rolling Hills Estates</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellevue</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sylvania</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Collegeville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clinton</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Brasil</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vitoria</city>
        <state>ES</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Juiz de Fora</city>
        <state>MG</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florian Polis</city>
        <state>Santa Catarina</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo Andre</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yanagawa</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hiroshima-shi</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chitose</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kitahiroshima</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Obihiro</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tomakomai</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Himeji</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naka-gun</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sakaide</city>
        <state>Kagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fujisawa-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nagaoka</city>
        <state>Niigata</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beppu</city>
        <state>Oita</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kurashiki-shi</city>
        <state>Okayama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Matsue</city>
        <state>Shimane</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuo</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kodaira</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nakano-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ohota-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kochi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tijuana</city>
        <state>Baja California</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <state>D.f.</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Morelia</city>
        <state>Michoacan</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Constanta</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tg. Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ekaterinburg</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <state>Russia</state>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladikavkaz</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dunajska Streda</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hnusta</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Komarno</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Levice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liptovsky Hradok</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liptovsky Mikulas</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rimavska Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruzomberok</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trencin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zvolen</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lyttleton</city>
        <state>Centurion</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <state>Kwazulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amanzimtoti</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durbanville</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Umkomaas</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vinytsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2010</study_first_posted>
  <results_first_submitted>July 1, 2013</results_first_submitted>
  <results_first_submitted_qc>July 1, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 10, 2013</results_first_posted>
  <last_update_submitted>October 11, 2013</last_update_submitted>
  <last_update_submitted_qc>October 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>dose finding</keyword>
  <keyword>asthma patients</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1144 participants were randomized. The first participant was enrolled on 19 October 2010 and the last participant completed the study on 16 February 2012.</recruitment_details>
      <pre_assignment_details>Participants were screened for a period of 31 days out of which 17 days for enrollment and 2 weeks for run-in period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD1981 400 mg</title>
          <description>AZD1981 400 mg twice daily</description>
        </group>
        <group group_id="P2">
          <title>AZD1981 200 mg</title>
          <description>AZD1981 200 mg once daily</description>
        </group>
        <group group_id="P3">
          <title>AZD1981 100 mg</title>
          <description>AZD1981 100 mg twice daily</description>
        </group>
        <group group_id="P4">
          <title>AZD1981 80 mg</title>
          <description>AZD1981 80 mg once daily</description>
        </group>
        <group group_id="P5">
          <title>AZD1981 40 mg</title>
          <description>AZD1981 40 mg twice daily</description>
        </group>
        <group group_id="P6">
          <title>AZD1981 10 mg</title>
          <description>AZD1981 10 mg twice daily</description>
        </group>
        <group group_id="P7">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="161">Two participants did not receive study treatment</participants>
                <participants group_id="P3" count="166">Two participants did not receive study treatment</participants>
                <participants group_id="P4" count="164"/>
                <participants group_id="P5" count="163">One participant excluded due to Good Clinical Practice (GCP) violation at centre 4323</participants>
                <participants group_id="P6" count="163"/>
                <participants group_id="P7" count="163">Two participants excluded due to Good Clinical Practice (GCP) violation at centre 4323</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="146"/>
                <participants group_id="P3" count="153"/>
                <participants group_id="P4" count="152"/>
                <participants group_id="P5" count="149"/>
                <participants group_id="P6" count="144"/>
                <participants group_id="P7" count="142"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="14"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="21"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Development of study withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="5"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Three patients (1 in the AZD1981 40 mg bid group and 2 in the placebo group) randomized at a Japanese centre were excluded from the analyses due to Good Clinical Practice violations identified after study completion.</population>
      <group_list>
        <group group_id="B1">
          <title>AZD1981 400 mg</title>
          <description>AZD1981 400 mg twice daily</description>
        </group>
        <group group_id="B2">
          <title>AZD1981 200 mg</title>
          <description>AZD1981 200 mg once daily</description>
        </group>
        <group group_id="B3">
          <title>AZD1981 100 mg</title>
          <description>AZD1981 100 mg twice daily</description>
        </group>
        <group group_id="B4">
          <title>AZD1981 80 mg</title>
          <description>AZD1981 80 mg once daily</description>
        </group>
        <group group_id="B5">
          <title>AZD1981 40 mg</title>
          <description>AZD1981 40 mg twice daily</description>
        </group>
        <group group_id="B6">
          <title>AZD1981 10 mg</title>
          <description>AZD1981 10 mg twice daily</description>
        </group>
        <group group_id="B7">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="164"/>
            <count group_id="B2" value="161"/>
            <count group_id="B3" value="166"/>
            <count group_id="B4" value="164"/>
            <count group_id="B5" value="162"/>
            <count group_id="B6" value="163"/>
            <count group_id="B7" value="161"/>
            <count group_id="B8" value="1141"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.6" spread="13.98"/>
                    <measurement group_id="B2" value="46.7" spread="12.84"/>
                    <measurement group_id="B3" value="46.4" spread="14.65"/>
                    <measurement group_id="B4" value="45.4" spread="13.22"/>
                    <measurement group_id="B5" value="46.3" spread="13.15"/>
                    <measurement group_id="B6" value="44.5" spread="13.76"/>
                    <measurement group_id="B7" value="45.7" spread="13.50"/>
                    <measurement group_id="B8" value="45.9" spread="13.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="87"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="82"/>
                    <measurement group_id="B6" value="80"/>
                    <measurement group_id="B7" value="76"/>
                    <measurement group_id="B8" value="561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="86"/>
                    <measurement group_id="B5" value="80"/>
                    <measurement group_id="B6" value="83"/>
                    <measurement group_id="B7" value="85"/>
                    <measurement group_id="B8" value="580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="120"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="121"/>
                    <measurement group_id="B6" value="113"/>
                    <measurement group_id="B7" value="119"/>
                    <measurement group_id="B8" value="824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="14"/>
                    <measurement group_id="B8" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since asthma diagnosis</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.6" spread="13.87"/>
                    <measurement group_id="B2" value="18.5" spread="14.25"/>
                    <measurement group_id="B3" value="18.6" spread="14.74"/>
                    <measurement group_id="B4" value="18.3" spread="13.04"/>
                    <measurement group_id="B5" value="18.0" spread="14.35"/>
                    <measurement group_id="B6" value="17.3" spread="12.40"/>
                    <measurement group_id="B7" value="17.5" spread="13.27"/>
                    <measurement group_id="B8" value="18.1" spread="13.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Former smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="15"/>
                    <measurement group_id="B8" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="137"/>
                    <measurement group_id="B3" value="152"/>
                    <measurement group_id="B4" value="143"/>
                    <measurement group_id="B5" value="136"/>
                    <measurement group_id="B6" value="144"/>
                    <measurement group_id="B7" value="146"/>
                    <measurement group_id="B8" value="997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pre-bronchodilator FEV1 percentage of predicted normal (PN) at randomization</title>
          <units>Percentage of predicted normal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.03" spread="10.544"/>
                    <measurement group_id="B2" value="68.86" spread="11.580"/>
                    <measurement group_id="B3" value="68.86" spread="11.774"/>
                    <measurement group_id="B4" value="68.56" spread="12.186"/>
                    <measurement group_id="B5" value="67.28" spread="11.732"/>
                    <measurement group_id="B6" value="69.06" spread="12.132"/>
                    <measurement group_id="B7" value="68.52" spread="11.319"/>
                    <measurement group_id="B8" value="68.73" spread="11.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total daily dose of inhaled glucocorticosteroids (ICS)</title>
          <units>µg</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="406.31" lower_limit="125.0" upper_limit="1000.0"/>
                    <measurement group_id="B2" value="399.75" lower_limit="100.0" upper_limit="1000.0"/>
                    <measurement group_id="B3" value="413.70" lower_limit="125.0" upper_limit="1000.0"/>
                    <measurement group_id="B4" value="396.46" lower_limit="150.0" upper_limit="500.0"/>
                    <measurement group_id="B5" value="405.56" lower_limit="160.0" upper_limit="1000.0"/>
                    <measurement group_id="B6" value="418.19" lower_limit="125.0" upper_limit="1000.0"/>
                    <measurement group_id="B7" value="410.99" lower_limit="160.0" upper_limit="1000.0"/>
                    <measurement group_id="B8" value="407.30" lower_limit="100.0" upper_limit="1000.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pre-bronchodilator FEV1 at the Clinic</title>
        <description>Change from baseline: treatment period average minus baseline. Treatment period average defined as the mean of all available data during randomized treatment that occurred on or prior to treatment failure. Treatment failure defined as worsening asthma symptoms resulting in increased dose of inhaled corticosteroid.</description>
        <time_frame>Twelve week treatment period</time_frame>
        <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD1981 400 mg</title>
            <description>AZD1981 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD1981 200 mg</title>
            <description>AZD1981 200 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD1981 100 mg</title>
            <description>AZD1981 100 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD1981 80 mg</title>
            <description>AZD1981 80 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD1981 40 mg</title>
            <description>AZD1981 40 mg twice daily</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - AZD1981 10 mg</title>
            <description>AZD1981 10 mg twice daily</description>
          </group>
          <group group_id="O7">
            <title>Arm7-Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator FEV1 at the Clinic</title>
          <description>Change from baseline: treatment period average minus baseline. Treatment period average defined as the mean of all available data during randomized treatment that occurred on or prior to treatment failure. Treatment failure defined as worsening asthma symptoms resulting in increased dose of inhaled corticosteroid.</description>
          <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="156"/>
                <count group_id="O3" value="162"/>
                <count group_id="O4" value="159"/>
                <count group_id="O5" value="158"/>
                <count group_id="O6" value="157"/>
                <count group_id="O7" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.16" lower_limit="0.10" upper_limit="0.21"/>
                    <measurement group_id="O2" value="0.19" lower_limit="0.14" upper_limit="0.25"/>
                    <measurement group_id="O3" value="0.19" lower_limit="0.13" upper_limit="0.24"/>
                    <measurement group_id="O4" value="0.15" lower_limit="0.10" upper_limit="0.21"/>
                    <measurement group_id="O5" value="0.20" lower_limit="0.15" upper_limit="0.26"/>
                    <measurement group_id="O6" value="0.15" lower_limit="0.10" upper_limit="0.21"/>
                    <measurement group_id="O7" value="0.14" lower_limit="0.08" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning and Evening PEF</title>
        <description>Change from baseline: treatment period average minus baseline. Treatment period average defined as the mean of all available morning (evening) PEF during randomized treatment that occurred on or prior to treatment failure. Treatment failure defined as worsening asthma symptoms resulting in increased dose of inhaled corticosteroid.</description>
        <time_frame>Twelve week treatment period</time_frame>
        <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD1981 400 mg</title>
            <description>AZD1981 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD1981 200 mg</title>
            <description>AZD1981 200 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD1981 100 mg</title>
            <description>AZD1981 100 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD1981 80 mg</title>
            <description>AZD1981 80 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD1981 40 mg</title>
            <description>AZD1981 40 mg twice daily</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - AZD1981 10 mg</title>
            <description>AZD1981 10 mg twice daily</description>
          </group>
          <group group_id="O7">
            <title>Arm 7-Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Morning and Evening PEF</title>
          <description>Change from baseline: treatment period average minus baseline. Treatment period average defined as the mean of all available morning (evening) PEF during randomized treatment that occurred on or prior to treatment failure. Treatment failure defined as worsening asthma symptoms resulting in increased dose of inhaled corticosteroid.</description>
          <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
          <units>Liters/minute</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="163"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="164"/>
                <count group_id="O5" value="161"/>
                <count group_id="O6" value="162"/>
                <count group_id="O7" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Morning PEF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.80" lower_limit="-0.99" upper_limit="12.59"/>
                    <measurement group_id="O2" value="0.60" lower_limit="-6.26" upper_limit="7.47"/>
                    <measurement group_id="O3" value="4.70" lower_limit="-2.06" upper_limit="11.46"/>
                    <measurement group_id="O4" value="0.06" lower_limit="-6.70" upper_limit="6.82"/>
                    <measurement group_id="O5" value="9.36" lower_limit="2.54" upper_limit="16.18"/>
                    <measurement group_id="O6" value="0.36" lower_limit="-6.44" upper_limit="7.16"/>
                    <measurement group_id="O7" value="-1.65" lower_limit="-8.49" upper_limit="5.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Evening PEF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.78" lower_limit="-6.15" upper_limit="7.72"/>
                    <measurement group_id="O2" value="-1.51" lower_limit="-8.54" upper_limit="5.52"/>
                    <measurement group_id="O3" value="-0.20" lower_limit="-7.11" upper_limit="6.71"/>
                    <measurement group_id="O4" value="-5.34" lower_limit="-12.25" upper_limit="1.57"/>
                    <measurement group_id="O5" value="7.20" lower_limit="0.21" upper_limit="14.19"/>
                    <measurement group_id="O6" value="-2.93" lower_limit="-9.88" upper_limit="4.02"/>
                    <measurement group_id="O7" value="0.27" lower_limit="-6.69" upper_limit="7.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Control Questionnaire 5-item (ACQ5)</title>
        <description>The ACQ5 consists of 5 questions, each assessed on a scale from 0-6, where 0 represents good asthma control and 6 represents poor asthma control. The overall score is the mean of the responses. The minimal important difference is defined as a change in score of 0.5. Change from baseline: treatment period average minus baseline.</description>
        <time_frame>Twelve week treatment period</time_frame>
        <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD1981 400 mg</title>
            <description>AZD1981 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD1981 200 mg</title>
            <description>AZD1981 200 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD1981 100 mg</title>
            <description>AZD1981 100 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD1981 80 mg</title>
            <description>AZD1981 80 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD1981 40 mg</title>
            <description>AZD1981 40 mg twice daily</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - AZD1981 10 mg</title>
            <description>AZD1981 10 mg twice daily</description>
          </group>
          <group group_id="O7">
            <title>Arm7-Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Control Questionnaire 5-item (ACQ5)</title>
          <description>The ACQ5 consists of 5 questions, each assessed on a scale from 0-6, where 0 represents good asthma control and 6 represents poor asthma control. The overall score is the mean of the responses. The minimal important difference is defined as a change in score of 0.5. Change from baseline: treatment period average minus baseline.</description>
          <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
          <units>Scores on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="157"/>
                <count group_id="O5" value="155"/>
                <count group_id="O6" value="152"/>
                <count group_id="O7" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.88" lower_limit="-1.00" upper_limit="-0.76"/>
                    <measurement group_id="O2" value="-0.88" lower_limit="-1.01" upper_limit="-0.76"/>
                    <measurement group_id="O3" value="-0.87" lower_limit="-0.99" upper_limit="-0.75"/>
                    <measurement group_id="O4" value="-0.90" lower_limit="-1.03" upper_limit="-0.78"/>
                    <measurement group_id="O5" value="-0.98" lower_limit="-1.10" upper_limit="-0.86"/>
                    <measurement group_id="O6" value="-0.83" lower_limit="-0.96" upper_limit="-0.71"/>
                    <measurement group_id="O7" value="-0.78" lower_limit="-0.91" upper_limit="-0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Number of participants who had at least one adverse event during the randomized treatment period</description>
        <time_frame>Twelve week treatment period</time_frame>
        <population>All randomized participants who received at least one dose of study medication and from whom any data after randomization was available</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD1981 400 mg</title>
            <description>AZD1981 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD1981 200 mg</title>
            <description>AZD1981 200 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD1981 100 mg</title>
            <description>AZD1981 100 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD1981 80 mg</title>
            <description>AZD1981 80 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD1981 40 mg</title>
            <description>AZD1981 40 mg twice daily</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - AZD1981 10 mg</title>
            <description>AZD1981 10 mg twice daily</description>
          </group>
          <group group_id="O7">
            <title>Arm7-Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Number of participants who had at least one adverse event during the randomized treatment period</description>
          <population>All randomized participants who received at least one dose of study medication and from whom any data after randomization was available</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="164"/>
                <count group_id="O5" value="163"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O6" value="56"/>
                    <measurement group_id="O7" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Severe Asthma Exacerbation</title>
        <description>Severe asthma exacerbation defined as deterioration in asthma leading to either hospitalization/emergency room treatment or oral glucocorticosteroid treatment for at least 3 days</description>
        <time_frame>Twelve week treatment period</time_frame>
        <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD1981 400 mg</title>
            <description>AZD1981 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD1981 200 mg</title>
            <description>AZD1981 200 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD1981 100 mg</title>
            <description>AZD1981 100 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD1981 80 mg</title>
            <description>AZD1981 80 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD1981 40 mg</title>
            <description>AZD1981 40 mg twice daily</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - AZD1981 10 mg</title>
            <description>AZD1981 10 mg twice daily</description>
          </group>
          <group group_id="O7">
            <title>Arm7-Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Severe Asthma Exacerbation</title>
          <description>Severe asthma exacerbation defined as deterioration in asthma leading to either hospitalization/emergency room treatment or oral glucocorticosteroid treatment for at least 3 days</description>
          <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="164"/>
                <count group_id="O5" value="162"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Treatment Failure</title>
        <description>Treatment failure is defined as a clinical need for additional inhaled corticosteroid use as judged by the investigator based on evaluations at the clinic.</description>
        <time_frame>Twelve week treatment period</time_frame>
        <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD1981 400 mg</title>
            <description>AZD1981 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD1981 200 mg</title>
            <description>AZD1981 200 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD1981 100 mg</title>
            <description>AZD1981 100 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD1981 80 mg</title>
            <description>AZD1981 80 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD1981 40 mg</title>
            <description>AZD1981 40 mg twice daily</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - AZD1981 10 mg</title>
            <description>AZD1981 10 mg twice daily</description>
          </group>
          <group group_id="O7">
            <title>Arm7-Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Treatment Failure</title>
          <description>Treatment failure is defined as a clinical need for additional inhaled corticosteroid use as judged by the investigator based on evaluations at the clinic.</description>
          <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="164"/>
                <count group_id="O5" value="162"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="12"/>
                    <measurement group_id="O7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Well-controlled Asthma (ACQ5&lt;=0.75)</title>
        <description>The ACQ5 consists of 5 questions, each assessed on a scale from 0-6, where 0 represents good asthma control and 6 represents poor asthma control. The overall score is the mean of the responses. Well-controlled asthma is defined as ACQ5&lt;=0.75 at the end of the 12-week treatment period.</description>
        <time_frame>Twelve week treatment period</time_frame>
        <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD1981 400 mg</title>
            <description>AZD1981 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD1981 200 mg</title>
            <description>AZD1981 200 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD1981 100 mg</title>
            <description>AZD1981 100 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD1981 80 mg</title>
            <description>AZD1981 80 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD1981 40 mg</title>
            <description>AZD1981 40 mg twice daily</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - AZD1981 10 mg</title>
            <description>AZD1981 10 mg twice daily</description>
          </group>
          <group group_id="O7">
            <title>Arm7-Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Well-controlled Asthma (ACQ5&lt;=0.75)</title>
          <description>The ACQ5 consists of 5 questions, each assessed on a scale from 0-6, where 0 represents good asthma control and 6 represents poor asthma control. The overall score is the mean of the responses. Well-controlled asthma is defined as ACQ5&lt;=0.75 at the end of the 12-week treatment period.</description>
          <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="159"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="164"/>
                <count group_id="O5" value="162"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="161"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="34"/>
                    <measurement group_id="O4" value="34"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="30"/>
                    <measurement group_id="O7" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Quality of Life Questionnaire (AQLQ(S))</title>
        <description>The AQLQ(S) consists of 32 questions, each assessed on a scale from 1-7, with higher values indicating better health-related quality of life. Overall scores are calculated from the means of the individual scores. The minimal important difference is a change in score of 0.5. Change from baseline: treatment period average minus baseline.</description>
        <time_frame>Twelve week treatment period</time_frame>
        <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD1981 400 mg</title>
            <description>AZD1981 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD1981 200 mg</title>
            <description>AZD1981 200 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD1981 100 mg</title>
            <description>AZD1981 100 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD1981 80 mg</title>
            <description>AZD1981 80 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD1981 40 mg</title>
            <description>AZD1981 40 mg twice daily</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - AZD1981 10 mg</title>
            <description>AZD1981 10 mg twice daily</description>
          </group>
          <group group_id="O7">
            <title>Arm7-Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Quality of Life Questionnaire (AQLQ(S))</title>
          <description>The AQLQ(S) consists of 32 questions, each assessed on a scale from 1-7, with higher values indicating better health-related quality of life. Overall scores are calculated from the means of the individual scores. The minimal important difference is a change in score of 0.5. Change from baseline: treatment period average minus baseline.</description>
          <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
          <units>Score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="156"/>
                <count group_id="O2" value="152"/>
                <count group_id="O3" value="160"/>
                <count group_id="O4" value="157"/>
                <count group_id="O5" value="155"/>
                <count group_id="O6" value="152"/>
                <count group_id="O7" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.60" upper_limit="0.85"/>
                    <measurement group_id="O2" value="0.73" lower_limit="0.61" upper_limit="0.86"/>
                    <measurement group_id="O3" value="0.75" lower_limit="0.63" upper_limit="0.87"/>
                    <measurement group_id="O4" value="0.80" lower_limit="0.68" upper_limit="0.92"/>
                    <measurement group_id="O5" value="0.82" lower_limit="0.69" upper_limit="0.94"/>
                    <measurement group_id="O6" value="0.72" lower_limit="0.59" upper_limit="0.84"/>
                    <measurement group_id="O7" value="0.65" lower_limit="0.53" upper_limit="0.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Asthma Symptom Score</title>
        <description>Asthma symptoms, measured in the morning and evening, based on a scale from 0-3 with higher scores indicating more severe asthma symptoms. Total asthma symptom score (0-6) is calculated by taking the sum of the morning and evening scores. Change from baseline: treatment period average minus baseline.</description>
        <time_frame>Twelve week treatment period</time_frame>
        <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD1981 400 mg</title>
            <description>AZD1981 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD1981 200 mg</title>
            <description>AZD1981 200 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD1981 100 mg</title>
            <description>AZD1981 100 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD1981 80 mg</title>
            <description>AZD1981 80 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD1981 40 mg</title>
            <description>AZD1981 40 mg twice daily</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - AZD1981 10 mg</title>
            <description>AZD1981 10 mg twice daily</description>
          </group>
          <group group_id="O7">
            <title>Arm7-Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Asthma Symptom Score</title>
          <description>Asthma symptoms, measured in the morning and evening, based on a scale from 0-3 with higher scores indicating more severe asthma symptoms. Total asthma symptom score (0-6) is calculated by taking the sum of the morning and evening scores. Change from baseline: treatment period average minus baseline.</description>
          <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
          <units>Score on scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="164"/>
                <count group_id="O5" value="162"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" lower_limit="-0.42" upper_limit="-0.18"/>
                    <measurement group_id="O2" value="-0.26" lower_limit="-0.38" upper_limit="-0.14"/>
                    <measurement group_id="O3" value="-0.28" lower_limit="-0.40" upper_limit="-0.16"/>
                    <measurement group_id="O4" value="-0.33" lower_limit="-0.45" upper_limit="-0.21"/>
                    <measurement group_id="O5" value="-0.34" lower_limit="-0.46" upper_limit="-0.22"/>
                    <measurement group_id="O6" value="-0.30" lower_limit="-0.42" upper_limit="-0.17"/>
                    <measurement group_id="O7" value="-0.27" lower_limit="-0.39" upper_limit="-0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Reliever Medication Use</title>
        <description>Reliever medication use (number of inhalations), measured in the morning and evening. Total reliever medication use is calculated by taking the sum of the number of daytime and evening inhalations of reliever medication. Change from baseline: treatment period average minus baseline.</description>
        <time_frame>Twelve week treatment period</time_frame>
        <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD1981 400 mg</title>
            <description>AZD1981 400 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>Arm 2 - AZD1981 200 mg</title>
            <description>AZD1981 200 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>Arm 3 - AZD1981 100 mg</title>
            <description>AZD1981 100 mg twice daily</description>
          </group>
          <group group_id="O4">
            <title>Arm 4 - AZD1981 80 mg</title>
            <description>AZD1981 80 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>Arm 5 - AZD1981 40 mg</title>
            <description>AZD1981 40 mg twice daily</description>
          </group>
          <group group_id="O6">
            <title>Arm 6 - AZD1981 10 mg</title>
            <description>AZD1981 10 mg twice daily</description>
          </group>
          <group group_id="O7">
            <title>Arm7-Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Total Reliever Medication Use</title>
          <description>Reliever medication use (number of inhalations), measured in the morning and evening. Total reliever medication use is calculated by taking the sum of the number of daytime and evening inhalations of reliever medication. Change from baseline: treatment period average minus baseline.</description>
          <population>The full analysis set consist of all randomized participants who received at least one dose of study medication and contributed sufficient data for at least the primary or secondary efficacy endpoint</population>
          <units>Number of inhalations</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="164"/>
                <count group_id="O2" value="158"/>
                <count group_id="O3" value="164"/>
                <count group_id="O4" value="164"/>
                <count group_id="O5" value="162"/>
                <count group_id="O6" value="163"/>
                <count group_id="O7" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" lower_limit="-0.72" upper_limit="-0.31"/>
                    <measurement group_id="O2" value="-0.22" lower_limit="-0.43" upper_limit="-0.01"/>
                    <measurement group_id="O3" value="-0.38" lower_limit="-0.58" upper_limit="-0.17"/>
                    <measurement group_id="O4" value="-0.39" lower_limit="-0.59" upper_limit="-0.18"/>
                    <measurement group_id="O5" value="-0.37" lower_limit="-0.58" upper_limit="-0.17"/>
                    <measurement group_id="O6" value="-0.37" lower_limit="-0.58" upper_limit="-0.17"/>
                    <measurement group_id="O7" value="-0.35" lower_limit="-0.56" upper_limit="-0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD1981 400 mg</title>
          <description>AZD1981 400 mg twice daily</description>
        </group>
        <group group_id="E2">
          <title>AZD1981 200 mg</title>
          <description>AZD1981 200 mg once daily</description>
        </group>
        <group group_id="E3">
          <title>AZD1981 100 mg</title>
          <description>AZD1981 100 mg twice daily</description>
        </group>
        <group group_id="E4">
          <title>AZD1981 80 mg</title>
          <description>AZD1981 80 mg once daily</description>
        </group>
        <group group_id="E5">
          <title>AZD1981 40 mg</title>
          <description>AZD1981 40 mg twice daily</description>
        </group>
        <group group_id="E6">
          <title>AZD1981 10 mg</title>
          <description>AZD1981 10 mg twice daily</description>
        </group>
        <group group_id="E7">
          <title>Placebo</title>
          <description>Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="32" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="21" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="159"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="164"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="164"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="163"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="163"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Holt</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

